Form 4: Myriad Genetics Executive Natalie Munk Reports Acquisition of 3,316 Shares of Common Stock

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the acquisition of 3,316 shares of common stock on February 7, 2025, related to performance-based restricted stock units.

Summary

• On February 7, 2025, Natalie Munk, Chief Accounting Officer of Myriad Genetics, acquired 3,316 shares of common stock.
• The acquisition was related to performance-based restricted stock units (PSUs) granted on March 22, 2022.
• The Compensation and Human Capital Committee determined the final award amount based on the accomplishment of pre-determined performance metrics.
• Each PSU represents a contingent right to receive one share of Myriad Genetics' common stock and vests on March 22, 2025.
• Following the transaction, Munk directly owns 46,575 shares of Myriad Genetics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by an executive suggests confidence, but it's a routine transaction related to compensation.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting of performance-based restricted stock units suggests that the company has met certain performance metrics.

Future Outlook

The acquired shares will vest on March 22, 2025, contingent on continued employment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future performance.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a company executive.

Key Dates